Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company's 2025 Annual General Meeting of ...

Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group ...

Pharming Group (NASDAQ:PHAR – Get Free Report) shares rose 10.3% during trading on Monday .The stock traded as high as $8.41 and last traded at $8.49. Approximately 5,462 shares changed hands ...

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended ...

Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million to $335 million, driven by the continued success of RUCONEST and Joenja.

(RTTNews) - Pharming Group N.V. (PHAR), a global biopharmaceutical company, on Thursday reported profit for the fourth quarter compared with loss last year. In the fourth quarter, net income came ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...

Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94. The stock has a market capitalization of $541.53 million, a P/E ratio of -30.62 and a beta of -0.10. Get Pharming Group alerts: ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about this conference ...

H.C. Wainwright reiterates a Buy rating on Pharming (PHAR) with a $37 price target after the company announced its intention to acquire Abliva AB for $66.1M. The firm believes the acquisition is ...

Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its ...

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 ...